Search for: "COBALT PHARMACEUTICALS"
Results 1 - 20
of 70
Sorted by Relevance
|
Sort by Date
11 Nov 2010, 9:59 pm
By James DeGiulio -- Roche Succeeds in Blocking Release of Cobalt's Generic Boniva Hoffman-La Roche successfully secured a preliminary injunction against Cobalt Pharmaceuticals in the patent suit over the bone-loss drug Boniva, thus preventing Cobalt from launching a generic version of the drug. [read post]
23 Dec 2010, 9:39 pm
District Court for the District of New Jersey rejected Cobalt Pharmaceuticals' attempt to invalidate Roche's patent covering Boniva for incorrect inventorship. [read post]
23 Mar 2009, 2:21 pm
Reddy's Laboratories, and Cobalt Pharmaceuticals. '639 claims an anti-epileptic drug that UCB markets as Keppra. [read post]
15 Apr 2007, 8:32 pm
Cobalt Pharmaceuticals, Inc. et. al.2:07-cv-01690; filed April 10, 2007 in the District... [read post]
26 Aug 2007, 9:33 pm
Cobalt Pharmaceuticals Inc.1:07-cv-04769; filed August 23, 2007 in the Northern District of Illinois Medpointe Healthcare... [read post]
21 Oct 2007, 7:40 pm
Cobalt Pharmaceuticals Inc. et al. v. [read post]
10 Nov 2007, 9:26 pm
King Pharmaceuticals filed its 10-Q statement with the SEC on Friday, revealing that Cobalt Pharmaceuticals, the first ANDA filer for Altace (ramipril), recently notified King of its intent to launch its generic ramipril product, notwithstanding the settlement agreement between the two parties (see pages 12 and 20 of King's 10-Q filing). [read post]
3 Feb 2021, 7:34 pm
Topics discussed include using blockchain for supply-chain management in various sectors, including the food supply and pharmaceutical industries, maritime shipping, the cobalt supply chain, self-sovereign identity, credentialing and records management. [read post]
26 May 2008, 9:11 pm
King Pharmaceuticals markets Altace (ramipril), which is indicated for the treatment of high blood pressure. [read post]
9 Apr 2008, 8:49 pm
By Donald Zuhn -- Last week, the Federal Circuit issued an opinion in Ortho-McNeil Pharmaceutical, Inc. v. [read post]
6 Nov 2007, 9:57 pm
Cobalt Pharmaceuticals submitted the first ANDA with a paragraph IV certification to the '722 patent in 2002, thereby earning 180-day exclusivity for ramipril (and thereby establishing this as a "pre-MMA" case). [read post]
4 Feb 2008, 8:46 am
Lupin argued first that Cobalt forfeited its 180-day exclusivity by entering into a settlement of its patent litigation with King Pharmaceuticals. [read post]
18 Nov 2008, 10:40 pm
., Impax Laboratories Inc. and Cobalt Laboratories Inc. in separate lawsuits for seeking generic approval for Cymbalta tablets. [read post]
21 Nov 2014, 4:00 am
Over the past few years the pharmaceutical marketplace has seen an increase in patent “re-litigation” (where a patentee is involved in a second case against another generic). [read post]
8 Oct 2007, 9:58 pm
Their letter explains: Cobalt Pharmaceuticals was the first ANDA filer and, as such, was eligible for 180-day exclusivity; Cobalt's ANDA was submitted prior to enactment of the 2003 Medicare Modernization Act, and therefore pre-MMA exclusivity provisions apply; Cobalt's ANDA contained a paragraph IV certification with respect to U.S. [read post]
14 Jun 2011, 2:14 pm
Stein Mitchell & Muse has filed one of the first local cases involving injuries due to artificial hip implants manufactured by DePuy Orthopaedics, a division of pharmaceutical giant Johnson & Johnson. [read post]
8 Nov 2007, 9:00 pm
Due to popular demand, I will have a separate section for Pharmaceutical Industry items from this week. [read post]
1 Mar 2015, 10:21 am
This defective hip released cobalt and chromium metallic debris into the body and the hip joint as the components grind against each other during normal use. [read post]
26 Jun 2008, 3:39 am
We reported last month that King Pharmaceuticals filed a citizen petition that could delay final approval of numerous ANDAs for generic versions of Altace (ramipril), which were set to earn final approval on June 7. [read post]
18 Jan 2021, 6:02 am
The two largest settlements in 2019 were Cobalt International Energy at $389.6 million and Alibaba Group Holding at $250 million… while the top 2020 settlements were the following: Valeant Pharmaceuticals – $1,210,000,000 American Realty Capital –$1,025,000,000 First Solar – $350,000,000 Signet Jewelers – $240,000,000 SCANA Corporation – $192,500,000 (more…) [read post]
